This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Abstract
Objective: Associations between peripheral neuropathy and restless legs syndrome (RLS) have been described, but have not been consistently reproduced. If RLS prevalence is truly increased by neuropathy, this has important implications for RLS pathophysiology.
Methods: In a case-control design, 245 patients with peripheral neuropathy and 245 age- and sex-matched controls were screened for RLS using a standardized phone questionnaire based on international RLS diagnostic criteria. All persons who answered yes to three of four criteria were considered screen-positive. All screen-positive patients underwent a confirmatory diagnostic evaluation by a movement disorders specialist blinded to the neuropathy status of the patient. RLS prevalence was calculated and compared using Fisher exact test.
Results: A total of 65 (26.5%) patients with neuropathy screened positive compared to 25 (10.2%) controls (p < 0.0001). However, the diagnosis was confirmed in only 46% of screen-positive patients with neuropathy, vs 80% of controls (p = 0.005). Cramps and paresthesia without true diurnal variation or rest exacerbation were the commonest causes of false-positive screens. After diagnostic confirmation, the overall prevalence of RLS did not differ between neuropathy patients and controls (12.2% vs 8.2%, p = 0.14). However, when classified by etiology, RLS was found in 14/72 (19.4%) patients with hereditary neuropathy, a prevalence higher than found in controls (p = 0.016) and acquired neuropathy (9.2%, p = 0.033). Among patients with neuropathy, those with RLS more commonly had a family history of RLS (37% vs 15%, p = 0.007) and were younger (49.9 vs 61.4, p = 0.0003).
Conclusions: Restless legs syndrome is more prevalent among patients with hereditary neuropathy, but not in those with acquired neuropathies.
CIDP = chronic inflammatory demyelinating polyneuropathy; GBS = Guillain-Barré syndrome; HMSN = hereditary motor sensory neuropathy; HSAN = hereditary sensory and autonomic neuropathy; IRLSSG = International Restless Legs Study Group; MGUS = monoclonal gammopathy of uncertain significance; NCS = nerve conduction studies; PPV = positive predictive value; RLS = restless legs syndrome.
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
More Online
Costs and Utilization of New-to-Market Neurologic Medications
Dr. Robert J. Fox and Dr. Mandy Leonard